![]() ![]() In a randomized trial involving patients with aortic stenosis, the use of a cerebral protection device during TAVR did not decrease the risk of periprocedural stroke, but there were fewer disabling strokes. Transcatheter Cardiovascular Therapeutics ConferenceĬerebral Embolic Protection during TAVR S.R. In a subgroup with faster-progressing disease, there was no clinical difference from placebo over a period of 28 weeks. The antisense molecule tofersen was tested intrathecally in 108 patients with ALS due to SOD1 mutations. Original Article Antisense Oligonucleotide for SOD1 ALS T.M.Sep 22Įditorial DELIVERing Progress in Heart Failure with Preserved Ejection Fraction In a trial involving patients with heart failure and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of worsening heart failure or cardiovascular death. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |